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Abstract
Measles virus nucleocapsid protein (MVNP) expression in osteoclasts (OCLs) and mutation of the 
SQSTM1 (p62) gene contribute to the increased OCL activity in Paget’s disease (PD). OCLs 
expressing MVNP display many of the features of PD OCLs. Interleukin-6 (IL-6) production is 
essential for the pagetic phenotype, because transgenic mice with MVNP targeted to OCLs 
develop pagetic OCLs and lesions, but this phenotype is absent when MVNP mice are bred to 
IL-6−/− mice. In contrast, mutant p62 expression in OCL precursors promotes receptor activator of 
NF-κB ligand (RANKL) hyperresponsivity and increased OCL production, but OCLs that form 
have normal morphology, are not hyperresponsive to 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3), 
nor produce elevated levels of IL-6. We previously generated p62P394L knock-in mice (p62KI) 
and found that although OCL numbers were increased, the mice did not develop pagetic lesions. 
However, mice expressing both MVNP and p62KI developed more exuberant pagetic lesions than 
mice expressing MVNP alone. To examine the role of elevated IL-6 in PD and determine if MVNP 
mediates its effects primarily through elevation of IL-6, we generated transgenic mice that 
overexpress IL-6 driven by the tartrate-resistant acid phosphatase (TRAP) promoter (TIL-6 mice) 
and produce IL-6 at levels comparable to MVNP mice. These were crossed with p62KI mice to 
determine whether IL-6 overexpression cooperates with mutant p62 to produce pagetic lesions. 
OCL precursors from p62KI/TIL-6 mice formed greater numbers of OCLs than either p62KI or 
TIL-6 OCL precursors in response to 1,25-(OH)2D3. Histomorphometric analysis of bones from 
p62KI/TIL-6 mice revealed increased OCL numbers per bone surface area compared to wild-type 
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(WT) mice. However, micro-quantitative CT (μQCT) analysis did not reveal significant 
differences between p62KI/TIL-6 and WT mice, and no pagetic OCLs or lesions were detected in 
vivo. Thus, increased IL-6 expression in OCLs from p62KI mice contributes to increased 
responsivity to 1,25-(OH)2D3 and increased OCL numbers, but is not sufficient to induce Paget’s-
like OCLs or bone lesions in vivo.
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Introduction
The primary cellular abnormality in Paget’s disease (PD) resides in the osteoclast 
(OCL).(1−3) OCLs are abundant in Paget’s lesions, and are larger, contain increased nuclei/
OCL, have increased bone resorbing capacity/OCL, increased 1,25-dihydroxyvitamin D3 
(1,25-(OH)2D3) and receptor activator of NF-κB ligand (RANKL) responsivity, and secrete 
high levels of interleukin 6 (IL-6), compared to normal OCLs.(4,5) Pagetic OCLs frequently 
express the measles virus nucleocapsid protein (MVNP),(6) which we have shown induces 
high levels of IL-6 expression in both human and mouse OCLs, and results in the 
development of pagetic OCLs and pagetic bone lesions in mice in vivo.(7,8) Further, high 
levels of IL-6 can induce TAF12, a vitamin D receptor (VDR) coactivator, in OCL 
precursors, which increases their responsivity to 1,25-(OH)2D3. Importantly, knockout of 
IL-6 in MVNP mice results in loss of their capacity to form pagetic lesions and OCLs,(9) 
suggests that IL-6 is required for MVNP to induce the development of PD.
There is also a genetic component to the etiology of PD, with up to 5% to 10% of all Paget’s 
patients carrying a germline mutation in the SQSTM1/p62 gene.(10) Expression of p62P392L, 
the most frequent mutation in p62 linked to PD in OCL precursors confers hyperresponsivity 
to RANKL but not 1,25-(OH)2D3, does not increase IL-6, and does not induce 
hypermultinucleated OCLs that occur in PD. Further, we found that knock-in mice (p62KI) 
carrying a p62P394L mutation (the murine equivalent of the most common human PD 
mutation, p62P392L) had modestly increased OCL numbers and developed mild osteopenia, 
but did not develop pagetic lesions.(11,12) However, when we crossed the p62KI and MVNP 
mice, the resulting p62KI/MVNP mice developed exuberant bone lesions that closely 
resembled PD lesions.(9) In addition, OCL precursors isolated from p62KI/MVNP mice were 
hyperresponsive to both RANKL and 1,25-(OH)2D3, expressed elevated IL-6, and formed 
hypermultinucleated OCLs that were similar to OCL from PD patients. These results suggest 
that increasing IL-6 expression in OCLs of p62KI mice may induce pagetic lesions and a 
pagetic phenotype in p62KI mice in vivo.
To test this hypothesis, we generated transgenic mice overexpressing IL-6 in OCLs driven 
by the tartrate-resistant acid phosphatase (TRAP) promoter (TIL-6 mice), and crossed them 
with the p62KI mice. OCL precursors from p62KI/TIL-6 mice were hyperresponsive to 
1,25-(OH)2D3 and RANKL compared to wild-type (WT). However, although these OCL 
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had increased numbers of nuclei/OCL, the nuclear number was lower than in MVNP mice. 
Further, p62KI/TIL-6 mice did not form pagetic OCLs or bone lesions in vivo.
PD is characterized by increases in both osteoclast and osteoblast activity; we found that 
both of these occur in MVNP but not the p62KI mice we generated. These results raise the 
question of why osteoblast activity is not induced in our previously reported p62KI mice. 
We found that in contrast to MVNP mice, osteoblasts from p62KI mice expressed much 
lower levels of Runx2 and osterix, transcription factors necessary for osteoblast 
differentiation, and higher levels of Dickkopf 1 (DKK1), a Wnt antagonist. Treatment of 
osteoblast precursors from p62KI mice with IL-6 did not increase Runx2 or osterix and did 
not decrease DKK1 levels. These results suggest that MVNP expression in OCL induces 
other factors in addition to IL-6, which are necessary for the development PD lesions in 
mice.
Subjects and Methods
Generation of TRAP-IL6 transgenic mice
All studies were approved by the Institutional Animal Care and Use Committees at Indiana 
University School of Medicine, the University of Pittsburgh School of Medicine, and 
Virginia Commonwealth University. To generate the TRAP-IL-6 transgene construct, a 1.1-
kb EcoRI endonuclease fragment containing a human IL-6 cDNA (ATCC cDNA number 
67153; American Type Culture Collection [ATCC], Manassas, VA, USA) was inserted into 
the unique EcoRI site of the pKCR3-mTRAP vector.(13,14) pKCR3-mTRAP contains 1.9 kb 
of the mouse TRAP gene promoter and 5′-untranslated region (UTR), in addition to rabbit β-
globin intron 2 and its flanking exons (for efficient transgene expression). A 4.2-kb injection 
fragment was then excised from the TRAP-IL-6 construct with Xhol restriction 
endonuclease, and transgenic mice were generated by standard methods in a CB6F1 
(C57Bl/6 × Balb/c) genetic background.(15) p62KI mice carrying a proline-to-leucine 
mutation at residue 394 (equivalent to human p62P392L) have been described.(11) TRAP-
MVNP transgenic mice have also been described.(8)
OCL formation from total transgenic mouse bone marrow
Bone marrow cells flushed from long bones of WT, p62KI, TIL-6, p62KI/TIL-6, or MVNP 
mice were cultured in 96-well plates (2 × 105 cells/well) with various concentrations of 
1,25-(OH)2D3 (Teijin Pharma, Tokyo, Japan) or RANKL (R&D, Minneapolis, MN, USA) 
as described. The end of cultures, cells were stained for TRAP using a leukocyte acid 
phosphatase kit (Sigma, St. Louis, MO, USA), and TRAP-positive cells (≥3 nuclei/cell) 
were scored as OCLs.
OCL formation from purified osteoclast precursors
OCL formation from CD11b+ cells was performed as described.(16) Nonadherent cells were 
harvested and enriched for CD11b+ mononuclear cells using the Miltenyi Biotec (Auburn, 
CA, USA) MACS (Magnetic Cell Sorting) system. CD11b+ cells then were cultured in α 
modified essential medium (α-MEM) containing 10% fetal calf serum (FCS) plus 10 ng/mL 
of macrophage colony-stimulating factor (M-CSF; R&D Systems, Minneapolis, MN, USA) 
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for 3 days to generate a population of enriched early OCL precursors. These cells were then 
cultured in α-MEM containing 10% FCS in the presence of 1,25-(OH)2D3 or RANKL for 3 
to 4 days to generate OCLs. The cells were then stained for TRAP and TRAP-positive cells 
(≥3 nuclei/cell) were scored as OCLs.
Bone resorption assays of cultured OCLs
Bone marrow cells were cultured on mammoth dentin slices (Wako, Osaka, Japan) in α-
MEM containing 10% FCS and 1,25-(OH)2D3 (1 × 10−8 M) or RANKL (100 ng/mL). After 
14 days of culture, the cells were removed, the dentin slices stained with acid hematoxylin, 
and the areas of dentin resorption determined using image-analysis techniques (NIH ImageJ 
System).
Immunoblotting of OCL precursor lysates from WT, p62KI, TIL-6, or p62KI/TIL-6 mice
Total proteins were extracted from formed OCL and loaded on SDS gels (Bio-Rad 
Laboratories, Hercules, CA, USA). Proteins were transferred to nitrocellulose membranes 
using a semidry blotter (Bio-Rad) and incubated in blocking solution (5% nonfat dry milk in 
Tris-buffered saline Tween-20 [TBST]) for 1 hour. Membranes were then exposed to 
primary antibodies overnight at 4°C, and incubated with immunoglobulin G (IgG) 
horseradish peroxidase (HRP)-conjugated antibody for 1 hour. The blots were washed and 
visualized by an Immobilon Western Chemiluminescent detection system (Thermo).
RANKL ELISA assay
Mouse marrow stromal cells were isolated as described(11) and cultured with 1,25-(OH)2D3 
for 7 days. Conditioned media from these cultures were harvested at the end of the culture 
period and the concentration of RANKL present was determined using an ELISA kit for 
mouse RANKL (R&D), according to the manufacturer’s instructions.
Quantitative microcomputed tomography measurements
The gross morphologic and microarchitectural characteristics of the distal area of the femur 
and L5 vertebra were examined by quantitative microcomputed tomography (μCT). The L5 
vertebrae were used for microquantitative CT (μQCT) to assess the trabecular bone, and the 
femurs were used to measure mean cortical thickness. A three-dimensional (3D) analysis 
was done to determine bone volume fraction (BV/TV, %), trabecular number (Tb.N, 
N/μm2), trabecular thickness (Tb.Th, μm), and trabecular bone spacing (Tb.Sp, μm). Cortical 
bone also was analyzed in the femur 2 mm below the growth plate, and the same 
segmentation parameters were used for analysis.
Bone histomorphometric analyses
Mice were given calcein (10 mg/kg) on day 7 and day 2 prior to euthanasia. Lumbar 
vertebrae from WT, p62KI/TIL-6, or TIL-6 mice were subjected to qualitative histological 
examination and histomorphometry. The decalcified sections were stained for TRAP, and 
OCL containing active TRAP were stained red. The undecalcified sections were left 
unstained for the evaluation of fluorescent labels. The analysis was performed on the 
cancellous bone/marrow compartment between the cranial and caudal growth plates in the 
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vertebral bodies without lesions using the OsteoMeasure XPTM version 1.01 morphometric 
programs (OsteoMetrics, Inc., Atlanta, GA, USA). Osteoclasts were defined as TRAP-
positive mononuclear and multinuclear cells. Osteoclast surface (Oc.S/BS), cancellous bone 
volume (BV/TV), trabecular thickness (Tb.Th), trabecular number (Tb.N), trabecular 
separation (Tb.Sp), mineralizing surface (MS/BS), mineral apposition rate (MAR), and bone 
formation rate (BFR/BS) were analyzed—calculated and expressed—according to the 
recommendations of the ASBMR Nomenclature Committee.(17)
Isolation of primary osteoblasts
After flushing out the bone marrow from tibias and femora of p62KI, MVNP, and WT mice, 
the tibia and femurs were cultured in α-MEM with 10% FCS for 7 to 10 days. The bones 
were then placed in 60-mm dishes and the cultures were continued in α-MEM containing 
10% FCS until cells growing out of the bones formed a confluent monolayer. The original 
bone was removed and the outgrowth cells from the bone were treated with 0.25% Trypsin 
and 0.05% EDTA for 10 minutes at 37°C. These cells were used as primary osteoblasts 
without further passage. The primary osteoblasts (2 × 105 cells/well in six-well plates) were 
cultured in α-MEM containing 10% FCS for 3 days and then IL-6 or vehicle was added for 
4 additional days. Cell lysates were collected with lysate buffer. This isolation method was 
previously used to establish the MC3T3-E1 cell line.(18)
von Kossa staining
Primary osteoblasts derived from WT, p62KI, and MVNP mice were cultured in 10% FCS in 
α-MEM for 3 weeks with the media changed every 3 days. The cells were then fixed with 
10% formaldehyde in PBS, and stained with von Kossa stain as described.(19)
Statistical analysis
For all cell culture studies, significance was evaluated using a two-tailed unpaired Student’s 
t test, with p < 0.05 considered to be significant.
Results
Characteristics of OCLs from WT, p62KI, TIL-6, p62KI/TIL-6, and MVNP mice
OCL precursors in total marrow cultures from MVNP mice, and to a lesser extent, p62KI/
TIL-6 mice, were hyperresponsive to 1,25-(OH)2D3 compared to p62KI, TIL-6, and WT 
mice, and formed increased numbers of OCLs at 1 × 10−10 to 1 × 10−8 M 1,25-(OH)2D3 
(Fig. 1A), suggesting that p62P394L and IL-6 can cooperate to promote an increased 
osteoclastogenic response to 1,25-(OH)2D3. OCLs from MVNP and p62KI/TIL-6 mice (and 
to a lesser extent TIL-6 mice) also had increased numbers of nuclei per OCL when treated 
with 1,25-(OH)2D3, compared to those from WT and p62KI mice (Fig. 1C, D). OCL 
precursors in marrow cultures from MVNP, p62KI/TIL-6, and p62KI mice also formed 
increased numbers of OCLs with RANKL treatment compared to TIL-6 and WT mice (Fig. 
1B), suggesting that IL-6 does not contribute significantly to RANKL responsivity. Bone 
resorption in response to 1,25-(OH)2D3 (1 × 10−8 M) and RANKL (100 ng/mL) was 
comparable in marrow cultures from MVNP and p62KI/TIL6 mice, which were > p62KI > 
TIL-6 > WT (Fig. 1E).
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OCL formation by highly purified populations of OCL precursors
OCL formation assays by highly purified populations of OCL precursors showed that only 
OCL precursors from TIL-6, p62KI/TIL-6, and MVNP mice were hyperresponsive to 1,25-
(OH)2D3, compared to WT and p62KI derived cultures (Fig. 2A), demonstrating that the 
increased 1,25-(OH)2D3 responsivity seen in total marrow cultures from the p62KI mice 
(Fig. 1A) resulted from effects of stromal cells in these cultures. However, the relative OCL 
formation in response to RANKL by pure populations of OCL precursors was identical to 
that from the total marrow cultures; ie, OCL precursors from p62KI, p62KI/TIL-6, and 
MVNP and mice were hyperresponsive to RANKL compared to those from TIL-6 or WT 
mice (Fig. 2B). The nuclear number per OCL also showed the same pattern of results as seen 
in OCLs formed from whole marrow cultures (Fig. 2C). These results are consistent with 
our previous results showing that mutant p62 contributes to RANKL hyperresponsivity 
directly in OCLs, whereas its contribution to increased 1,25-(OH)2D3 responsivity is 
mediated through effects on stromal cells.(11) In contrast, IL-6 contributes to 1,25-(OH)2D3 
responsivity directly in OCLs, but does not appear to have an affect on OCL response to 
RANKL.
We recently reported that IL-6 induces expression of TAF12, a novel coactivator of VDR-
mediated transcription that is increased in OCLs from PD patients and MVNP mice.(20) 
Therefore, we determined if TAF12 expression was increased in OCLs from p62KI, TIL-6, 
and p62KI/TIL-6 mice. OCLs formed by highly purified OCL precursors from TIL-6 and 
p62KI/TIL-6 mice expressed elevated levels of TAF12 compared to WT (Fig. 2D). In 
contrast, TAF12 was not increased in OCLs from p62KI mice.
RANKL expression by marrow stromal cells derived from WT, p62KI, TIL-6, p62KI/TIL-6, 
and MVNP mice
We previously found that marrow stromal cells from p62KI but not MVNP mice have 
increased expression of TAF12 which resulted in enhanced RANKL production by the 
stromal cells when treated with low concentrations of 1,25-(OH)2D3.(7,8). Therefore, we 
measured RANKL production by stromal cells from p62KI, TIL-6, p62KI/TIL-6, MVNP, 
and WT mice. Stromal cells from p62KI/TIL-6 and p62KI mice treated with 1,25-(OH)2D3 
produced increased levels of RANKL when treated with 1 × 10−10 M 1,25-(OH)2D3 (Fig. 
3A). Interestingly, p62KI/TIL-6 stromal cells produced twofold more secreted RANKL than 
p62KI stromal cells (Fig. 3B). Both the RANKL/osteoprotegerin (OPG) ratio (Fig. 3A) and 
TAF12 levels (Fig. 3C) were markedly increased in stromal cells from p62KI/TIL-6 mice 
but not in MVNP mice. These results demonstrate that high levels of IL-6 produced by 
TIL-6 mice also induce TAF12 in marrow stromal cells, which enhances their responsivity 
to 1,25-(OH)2D3 and results in increased RANKL production by stromal cells from p62KI/
TIL-6 mice treated with 1,25-(OH)2D3.
Next we examined if WT, p62KI, TIL-6, p62KI/TIL-6, and MVNP stromal cells 
differentially supported OCL formation. Stromal cells were cocultured with colony-forming 
unit–granulocytemacrophage (CFU-GM)-derived cells (OCL precursors) from WT mice 
with 1 × 10−8 M 1,25-(OH)2D3 or vehicle for 7 days. As shown in Fig. 3D, stromal cells 
derived from p62KI/TIL-6 mice, and to a lesser extent p62KI mice, had an increased 
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capacity to support OCL formation in response to 1,25-(OH)2D3. Because stromal cells from 
MVNP mice do not express increased TAF12, they did not increase OCL formation when 
cocultured with WT OCL precursors treated with 1,25-(OH)2D3 (Fig. 3D).
Bone phenotype of p62KI/TIL-6 mice
To determine whether coexpression of mutant p62 and IL-6 in the bone promote the 
development of pagetic lesions, we examined lumbar vertebral bone from p62KI, TIL-6, 
p62KI/TIL-6, and WT mice at 12 months of age by qualitative histology and 
histomorphometry, and femurs and L5 vert6ebra by μCT. No pagetic lesions were found in 
the lumbar vertebrae of any of these mice. Further, μQCT histomorphometric analysis 
revealed no significant differences between mice of any of the four genotypes in bone 
structural variables (cancellous BV/TV, Tb.N, Tb.Wi, Tb.Sp) (Table 1), nor in the 
mineralized surface (Md.Pm), MAR, and BFR (Fig. 4). Only OCL numbers per bone surface 
were significantly increased in both p62KI and p62KI/TIL-6 mice (Fig. 4).
Expression of OCL fusion molecules in OCL precursors
Because OCL precursors from MVNP mice and pagetic patients expressing MVNP form 
OCLs with increased nuclei per OCL, we measured the expression levels of several fusion 
molecules in MVNP, p62KI, and WT OCL precursors treated with IL-6 for 4 days. OCLs 
formed from MVNP mice with or without IL-6 treatment had elevated expression of 
dendritic cell-specific transmembrane protein (DC-STAMP) compared with those from 
p62KI and WT mice (Fig. 5). The expression levels of the d2 isoform of the v-ATPase V0 
domain (ATP6v0d2) and a distintegrin and a metalloproteinase domain-8 (ADAM8) were 
only modestly elevated in MVNP OCL (Fig. 5).
Effect of IL-6 on osteoblast differentiation
Our previous data demonstrated that IL-6 was required to increase bone formation and 
induce a pagetic phenotype in MVNP mice.(4) It was thus our hypothesis that increasing IL-6 
expression in OCLs of p62KI mice would result in development of a pagetic bone lesions in 
p62KI/TIL-6 mice. We therefore examined the effects of IL-6 on osteoblast differentiation 
by primary osteoblasts from p62KI, MVNP, and WT mice.
We found that there was a twofold increase in the levels of Runx2 and Osterix in osteoblasts 
from MVNP mice compared with WT and p62KI mice. These parameters were not affected 
by IL-6 treatment of WT, MVNP, or p62KI osteoblasts (Fig. 6A). In contrast, IL-6 treatment 
of MVNP osteoblasts modestly enhanced alkaline phosphatase (ALP) expression. The levels 
of osteocalcin expression were not different in WT, p62KI, and MVNP osteoblasts and IL-6 
did not increase osteocalcin expression (Fig. 6A). Because high expression levels of 
Dickkopf 1 (Dkk1) can inhibit osteoblast differentiation,(21) we measured Dkk1 levels in 
WT, p62KI, and MVNP osteoblasts. Dkk1 expression in p62KI osteoblasts was elevated 
twofold and increased to 3.8-fold with IL-6 treatment (Fig. 6A). In contrast, MVNP and WT 
osteoblasts had much lower levels of Dkk1 that were not affected by IL-6 treatment (Fig. 
6A). Osteoblast (OB)-cadherin and ALP were decreased in the p62KI mice compared to WT 
and MVNP, and were inversely correlated with Dkk1 expression, which was elevated in 
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p62KI compared to WT and MVNP; RUNX2 and osterix were induced twofold in MVNP 
mice.
We then measured the mineral deposition capacity of the osteoblasts by von Kossa staining. 
MVNP osteoblast cultures showed increased numbers of calcified areas compared with 
cultures of p62KI and WT osteoblasts (Fig. 6B). These results suggest that the osteoblast 
differentiation capacity of osteoblast from p62KI mice is much lower than osteoblast from 
MVNP mice.
Discussion
Both environmental elements and genetic causes both contribute to PD. We found that the 
expression of both MVNP and the SQSTM1 (p62) mutation P392L in OCLs contribute to the 
increased OCL activity in PD, and we have reported that p62P392L knock-in mice do not 
develop pagetic lesions unless MVNP is also present. When MVNP is present with the 
p62KI mutation, mice develop exuberant pagetic lesions very similar to those seen in 
patients with PD of bone. However, Daroszewska and colleagues(22) reported that a similar 
p62P394L knock-in mouse develops small focal lesions which showed increases in bone 
turnover with increased bone resorption and formation, disruption of the normal bone 
architecture, and an accumulation of woven bone. The basis for the differences in these two 
knock-in models is unclear at this time but demonstrate that the capacity of mutant p62 to 
induce pagetic lesions in vivo is variable. MVNP, but not p62KI, mice have increased IL-6 
production and loss of IL-6 blocks the effects of MVNP in PD.(9,11,12) These results suggest 
p62KI in combination with high IL-6 in OCL may result in PD. To address this question, we 
generated p62KI/TIL-6 transgenic mice by breeding p62KI mice to TIL-6 mice in which 
overexpression of IL-6 is driven by the TRAP promoter, and characterized their OCLs and 
bone phenotype.
OCL precursors from p62KI/TIL-6 mice formed OCL that expressed an intermediate pagetic 
phenotype in vitro (Fig. 1). The OCLs were hyperresponsive to 1,25-(OH)2D3 and RANKL, 
formed OCL with increased bone resorbing capacity and elevated levels of TAF12 but 
developed only modest multinuclearity (Figs. 1, 2) compared to MVNP mice.
In contrast, OCL precursors from p62KI and WT mice were not hyperresponsive to 1,25-
(OH)2D3, expressed normal levels of TAF12, and formed normal OCLs.(11) Only OCL 
precursors from p62KI/TIL-6 were hyperresponsive to RANKL, whereas both p62KI/TIL-6 
and TIL-6 cells had increased STAT3 signaling (Fig. 2D). p62KI and WT OCL had normal 
ratios of nuclei/OCL when treated with 1,25-(OH)2D3 or RANKL. These results suggested 
that expression of IL-6 in p62KI OCL precursors is required for OCLs to express a pagetic 
phenotype in vitro, and that high levels of IL-6 enhances OCL precursor fusion in p62KI 
mice. The enhanced OCL precursor fusion in MVNP mice most likely reflects the increased 
expression of DC-STAMP(23,24) in their OCL precursors, which was enhanced by IL-6 
treatment (Fig. 5). DC-STAMP appears to be increased selectively in MVNP OCL 
precursors compared with other fusion molecules associated with increased OCL precursor 
fusion (eg, D44, CD48, and ADAM8), and was not increased significantly in p62KI and WT 
OCL precursors (Fig. 5). Lee and colleagues(25) reported that increased nuclear factor of 
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activated T cells, cytoplasmic 1 (NFATc1) through upregulation of c-Fos increased 
expression of DC-STAMP. Because IL-6 increases expression of c-Fos and NFATc1, this 
may explain its capacity to enhance DC-STAMP expression. ATP6v0d2 also was 
upregulated modestly (1.8-fold) in MVNP OCL precursors. This mostly reflects that 
NFATc1 can also enhance expression of this fusion molecule.(26) Further, IL-6 enhances 
p38 mitogen-activated protein kinase (MAPK) signaling in MVNP OCL precursors (data not 
shown), which may also contribute to the hypermultinuclearity of OCLs formed in marrow 
cultures from MVNP mice. We previously reported that enhanced p38 MAPK signaling 
plays a critical role in the increased nuclear number per OCL in OCLs expressing the 
measles virus nucleocapsid gene.(9)
Marrow stromal cells from p62KI/TIL-6 expressed higher levels of RANKL in response to 
1,25-(OH)2D3 than the other mouse marrow stromal cells (Fig. 3A). The RANKL/OPG 
expression ratio in stromal cells from p62KI/TIL-6 was increased 3.5-fold compared with 
WT (Fig. 3A). The stromal cells from p62KI/TIL-6 also expressed high levels of TAF12. 
The expression of TAF12 in stromal cells can result in hyperresponsivity to 1,25-(OH)2D3 
and increased VDR transcription because at high levels, TAF12 acts as a coactivator of 
VDR transcription.(20) Why p62KI/TIL-6 had higher expression of RANKL compared with 
p62KI stromal cells is not clear. Possibly, p62P394L and IL-6 have additive effects on VDR-
TAF12 mediated transcription. These findings may in part explain the enhanced RANKL 
production present in the marrow microenvironment of pagetic patients.
p62KI/TIL-6 mice did not develop pagetic bone lesions or structural characteristics seen in 
pagetic patients. They only had increased OCL perimeter scores (Fig. 4A). In contrast, 
dynamic bone formation variables were similar to those in WT mice (Fig. 4, Table 1). These 
results suggest IL-6 is not enhancing osteoblast activity. Franchimont and colleagues(27) 
report that IL-6 can modulate osteoblast proliferation, differentiation, and apoptosis, and 
supports osteoblast generation. However, as shown in Fig. 6, IL-6 only increased ALP 
expression in osteoblasts from MVNP mice. These results suggest high levels of IL-6 are not 
sufficient to induce the enhanced bone formation characteristic of PD.
Interestingly, p62KI osteoblasts had increased expression of the Wnt signaling antagonist, 
Dkk1, which was further increased by IL-6 (Fig. 6A). Naot and colleagues(28) reported 
increased expression of Dkk1 in osteoblast cultures from Paget’s patients. The canonical 
Wnt pathway plays a key role in regulating osteoblast proliferation and differentiation.(29) 
Tian and colleagues(21) have suggested that the release of Dkk1 from malignant plasma cells 
in multiple myeloma results in an inhibition of osteoblast proliferation, accentuating the 
imbalance between bone formation and bone resorption and facilitating local bone loss. In 
the p62KI/TIL-6 mice, overproduction of Dkk1 in osteoblasts could have a similar effect on 
bone formation. Possibly increased levels of IL-6 are responsible for the overexpression of 
Dkk1 in PD and contribute to the development of the lytic phase of PD through further 
accelerating local bone turnover. These results may explain in part why p62KI/TIL-6 mice 
did not develop pagetic lesions in vivo.
In summary, these results demonstrate that p62P394L and IL-6 in combination increase OCL 
formation and activity, but are not sufficient to induce pagetic OCL and bone lesions 
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characteristic of PD in vivo. Further, based on our findings that loss of IL-6 in MVNP mice 
results in loss of their pagetic phenotype, these results demonstrate that IL-6 is necessary but 
not sufficient to induce PD. These data further demonstrate that expression of high IL-6 in 
OCL confers many of characteristics of PD OCL (hyperresponsivity to 1,25-(OH)2D3, 
increased nuclei/OCL, increased bone resorption) but is not sufficient by itself or in 
combination with p62P394L to induce PD. Thus, other factors induced by MVNP may also be 
required to enhance bone formation characteristics of PD, such as coupling factors or 
osteoblast stimulating factors. Recently, we found that MVNP but not p62P394L increased 
expression of ephrinB2/EphB4, insulin-like growth factor 1 (IGF1), and semaphorin3A, 
suggesting MVNP has multiple effects beyond upregulating IL-6 to induce PD (ASBMR 
2013 Abstract).(30)
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Osteoclast formation in whole bone marrow cultures from WT, p62KI, TIL-6, p62KI/TIL-6, 
and MVNP mice. (A) OCL formation by treatment of 1,25-(OH)2D3. Data are expressed as 
the mean ± SD (n = 4); *p < 0.01, significantly different from OCLs formed with the same 
treatment in WT mouse cultures. (B) OCL formation by treatment of RANKL. Data are 
expressed as the mean ± SD (n = 4); *p < 0.01, significantly different from OCLs formed 
with the same treatment in WT mouse cultures. (C) Phenotype of OCLs formed from mouse 
bone marrow cultures. OCLs formed by 1,25-(OH)2D3 (1 × 10−8 M) were stained for TRAP. 
Magnification ×100. (D) Nuclei per OCL. The nuclear numbers per OCL were randomly 
counted in 25 OCLs formed in 1 × 10−8 M 1,25-(OH)2D3 or 100 ng/mL RANKL-treated 
cultures as in A and B. Data are expressed as the mean ± SD (n = 25); *p < 0.01, 
significantly different from OCLs formed with the same treatment in WT mouse cultures. 
(E) Bone resorption capacity of OCLs. Bone marrow cells were cultured for 7 days with 
1,25-(OH)2D3 (1 × 10−8 M) or RANKL (100 ng/mL) on mammoth dentin slices. Values 
represent the amount of dentin surface resorption (%), mean ± SD (n = 4). WT = wild = 
type; OCL = osteoclast; 1,25-(OH)2D3 = 1,25-dihydroxyvitamin D3; TRAP = tartrate-
resistant acid phosphatase; RANKL = receptor activator of NF-κB ligand.
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Osteoclast formation formed by CD11b+ cells from WT, p62KI, TIL-6, p62KI/TIL-6, and 
MVNP mice. (A) OCL formation by 1,25-(OH)2D3. Data are expressed as the mean ± SD (n 
= 4); *p < 0.01, significantly different from OCLs formed with the same treatment in WT 
mouse cultures. (B) OCL formation by RANKL. Data are expressed as the mean ± SD (n = 
4); *p < 0.01, significantly different from OCLs formed with the same treatment in WT 
mouse cultures. (C) Nuclei per OCL. The nuclear number per OCL was determined by 
randomly scoring 25 OCLs formed in 1 × 10−8 M 1,25-(OH)2D3 or 100 ng/mL of RANKL-
treated cultures. Data are expressed as the mean ± SD (n = 25); *p < 0.01, significantly 
different from OCLs formed with the same treatment in WT mouse cultures. (D) TAF12 
expression in OCLs. CD11b+ mononuclear cells were treated with 10 ng/mL of M-CSF for 3 
days, then cultured with RANKL (100 ng/mL) for 4 days and cell lysates were collected. 
TAF12 expression was analyzed by immunoblot using antibodies recognizing TAF12 
(ProteinTech). TFIIB was used as a loading control. WT = wild-type; RANKL = receptor 
activator of NF-κB ligand; OCL = osteoclast; 1,25-(OH)2D3 = 1,25-dihydroxyvitamin D3; 
M-CSF = macrophage colony-stimulating factor; TFIIB = transcription factor IIB.
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Support of OCL formation by marrow stromal cells from WT, p62KI, TIL-6, p62KI/TIL-6, 
and MVNP mice. (A) RANKL and OPG expression. Stromal cells from WT, p62KI, TIL-6, 
p62KI/TIL-6, and MVNP mice were cultured with 1,25-(OH)2D3 (1 × 10−8 M) for 2 days, 
the cell lysates were collected, and the levels of RANKL and OPG were determined by 
Western blot analysis using anti-RANKL and anti-OPG antibodies (Santa Cruz 
Biotechnology, Santa Cruz, CA, USA). The ratio of RANKL/OPG expression levels from 
Western blots were quantitated by densitometry using WT cultures as 1.0. (B) RANKL 
production by mouse marrow stromal cells. Mouse marrow stromal cells were cultured with 
1,25-(OH)2D3 for 7 days. Conditioned media from these cultures were harvested at the end 
of the culture period and the concentration of RANKL present was determined. The data is 
shown as mean ± SD (n = 4); *p < 0.01 compared with WT cells cultured with the same 
concentration of 1,25-(OH)2D3. (C) TAF12 expression in marrow stromal cells. Stromal 
cells were cultured with 10% FCS in IMDM for 3 days and then cell lysates were collected. 
TAF12 expression was analyzed by immunoblot using a polyclonal antibody recognizing 
TAF12. TFIIB was used as a loading control. (D) Support of OCL formation by marrow 
stromal cells. Stromal cells from WT, p62KI, TIL-6, p62KI/TIL-6, and MVNP mice were 
cocultured with CFU-GM derived from WT mouse bone marrow in the presence of 1 × 10−8 
M 1,25-(OH)2D3 for 7 days. The cells were then fixed and stained for TRAP, and the 
TRAP-positive OCLs were counted. Results are expressed as the mean ± SD (n = 4); *p < 
0.01 compared with results in WT cultures. OCL = osteoclast; WT = wild-type; RANKL = 
receptor activator of NF-κB ligand; OPG = osteoprotegerin; 1,25-(OH)2D3 = 1,25-
dihydroxyvitamin D3; FCS = fetal calf serum; IMDM = Iscove’s Modi fied Dulbecco’s 
Media; TFIIB = transcription factor IIB; CFU-GM = colony-forming unit–
granulocytemacrophage; TRAP = tartrate-resistant acid phosphatase.
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Histomorphometric analysis of WT, TIL-6, p62KI, and p62KI/TIL-6 lumbar vertebra from 
12-month-old. (A) OC.Pm, (B) Md.Pm, (C) MAR, and (D) BFR for WT, TIL-6, p62KI, and 
p62KI/TIL-6 mice are shown. Data represent mean ± SD for WT (7 male, 7 female), p62KI 
(6 male, 7 female), TIL-6 (7 male, 10 female), and p62KI/TIL-6 (3 male, 10 female) mice 
per group. *p < 0.01 significant differences between WT and p62KI/TIL-6 mice were 
detected. WT = wild-type; OCL = osteoclast; OC.Pm = OCL surface; Md.Pm = mineralized 
surface; MAR = mineral apposition rate; BFR = bone formation rate.
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The expression of fusion molecules in WT, p62KI, and MVNP OCL precursors. CD11b+ 
mononuclear cells were treated with 10 ng/mL M-CSF for 3 days, then treated with or 
without mouse IL-6 (10 ng/mL) (R&D) and mouse IL-6 receptor (10 ng/mL) (R&D) for 4 
days. Cell lysates were analyzed by immunoblot using antibodies recognizing DC-STAMP 
(Cosmo Bio Co. Ltd, Tokyo, Japan), ATP6v0d2 (Abnova Co., Taipei, Taiwan), ADAM8 
(Santa Cruz Biotechnology, Santa Cruz, CA, USA), and β-actin (Abcam, Cambridge, MA, 
USA) as a loading control. WT = wild-type; OCL = osteoclast; M-CSF = macrophage 
colony-stimulating factor; IL-6 = interleukin 6; DC-STAMP = dendritic cell-speci fic 
transmembrane protein; ATP6v0d2 = the d2 isoform of the v-ATPase V0 domain; ADAM8 
= a distintegrin and a metalloproteinase domain-8.
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Osteoblast differentiation markers in osteoblasts derived from WT, p62KI, and MVNP mice. 
(A) Expression of osteoblast differentiation markers. Primary osteoblasts (2 × 105 cells/35-
mm dish) were cultured with or without 10 ng/mL of IL-6 for 4 days in 10% FCS in α-
MEM. Cell lysates were analyzed by immunoblot using antibodies recognizing OB-
Cadherin (Cell Signaling, Beverly, MA, USA), alkaline phosphatase (Millipore, Billerica, 
MA, USA), Runx2 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), Osterix (Abcam, 
Cambridge, MA, USA), osteocalcin (Millipore), Dkk1 (Cell Signaling), and β-actin 
(Abcam) as loading control. (B) Calcification in vitro. Osteoblasts were cultured in 10% 
FCS with α-MEM for 3 weeks as described in Subjects and Methods. The cells were stained 
with von Kossa stain (×100). WT = wild-type; IL-6 = interleukin 6; FCS = fetal calf serum; 
α-MEM = α modified essential medium.
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BV/TV (%) 13.4±2.1 13.1±5.9 13.5±5.8 14.6±4.5 13.3±5.6 11.9±4.3 10.2±2.5 11.2±3.9
Tb.Th (μm) 31.4±3.1 33.1±5.6 36.2±8.5 33.1±5.0 33.3±4.5 35.5±5.3 35.5±3.6 37.1±9.8
Tb.N (1/mm2) 4.3±0.4 3.8±1.1 3.7±1.3 4.4±0.9 4.0±1.6 3.5±1.7 2.9±0.6 3.0±0.1
Tb.Sp (μm) 204.4±22.3 248.1±86.0 265.4±121.9 203.0±48.1 239.6±73.0 312.0±169.1 327.1±84.3 313.0±84.2
Structural variables for the lumbar vertebral bodies from 12-month-old WT, p62KI, TIL-6, and p62KI/TIL-6 mice. Data are expressed as mean ± 
SD. No significant differences between WT and other mice in all the variables.
WT = wild-type; BV/TV = cancellous bone volume; Tb.Th = trabecular thickness; Tb.N = trabecular number; Tb.Sp = trabecular separation.
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